New Delhi: Drug firm Suven Life Sciences today said it has received a total of three product patents for CNS molecules, which could be used for treating various central nervous system disorders.The product patents -- two from Canada and one from Eurasia -- are valid through 2028, Suven Life Sciences said in a BSE filing.The company has received approval for molecules that could be used in the treatment of neuro-degenerative disorders like Parkinson, Alzheimer`s disease and Schizophrenia, it added.
Moeen warned over pro-Gaza Test wristbands
ISIS opens `marriage bureau` in Syria
Farmers should get better technology: PM
Delhi shame: Class 10th student gang-raped in Uttam Nagar at gun point